InsiderTrades.com logo

Shannon Kelley Biography and Net Worth

General Counsel of Madrigal Pharmaceuticals
  • LinkedIn
  • Phone
  • Email
  • Website


Ms. Kelley has more than 20 years of diverse healthcare experience as a compliance and legal professional which will support Madrigal’s responsible growth. She joined Madrigal from Sanofi, where she served in roles of increasing responsibility. She was most recently Vice President, Chief Compliance Officer, North America and Global Specialty Care, responsible for compliance across all therapeutic areas. Prior to Sanofi, Ms. Kelley was Global Compliance and Commercial Legal Counsel for Boston Scientific Corporation. Earlier in her career, she spent ten years in enforcement roles with the U.S. Federal Government. Ms. Kelley was a Trial Attorney for the Department of Justice in Washington, D.C. and an Assistant United States Attorney and Deputy Chief of Litigation for the U.S. Attorney’s Office for the District of Massachusetts focused on healthcare matters. She is a member of the Massachusetts, D.C. and Federal bars.

What is Shannon T. Kelley's net worth?

The estimated net worth of Shannon T. Kelley is at least $2.53 million as of January 17th, 2025. Ms. Kelley owns 7,705 shares of Madrigal Pharmaceuticals stock worth more than $2,526,238 as of March 29th. This net worth evaluation does not reflect any other investments that Ms. Kelley may own. Learn More about Shannon T. Kelley's net worth.

How do I contact Shannon T. Kelley?

The corporate mailing address for Ms. Kelley and other Madrigal Pharmaceuticals executives is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. Madrigal Pharmaceuticals can also be reached via phone at (267) 824-2827 and via email at ir@madrigalpharma.com. Learn More on Shannon T. Kelley's contact information.

Has Shannon T. Kelley been buying or selling shares of Madrigal Pharmaceuticals?

Within the last three months, Shannon T. Kelley has sold $75,734.57 of Madrigal Pharmaceuticals stock. Most recently, Shannon T. Kelley sold 277 shares of the business's stock in a transaction on Friday, January 17th. The shares were sold at an average price of $273.41, for a transaction totalling $75,734.57. Following the completion of the sale, the general counsel now directly owns 7,705 shares of the company's stock, valued at $2,106,624.05. Learn More on Shannon T. Kelley's trading history.

Who are Madrigal Pharmaceuticals' active insiders?

Madrigal Pharmaceuticals' insider roster includes Fred Craves (Director), James Daly (Director), Paul Friedman (Director), Carole Huntsman (Chief Commercial Officer), Shannon Kelley (General Counsel), Richard Levy (Director), Brian Lynch (SVP), William Sibold (CEO), Remy Sukhija (Sr. VP & Chief Commercial Officer), Rebecca Taub (Director, Founder, Chief Medical Officer and President of Research & Development), and Robert Waltermire (VP). Learn More on Madrigal Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Madrigal Pharmaceuticals?

During the last twelve months, insiders at the biopharmaceutical company sold shares 25 times. They sold a total of 228,184 shares worth more than $55,041,951.49. The most recent insider tranaction occured on March, 5th when VP Robert E Waltermire sold 14,113 shares worth more than $4,817,049.16. Insiders at Madrigal Pharmaceuticals own 22.8% of the company. Learn More about insider trades at Madrigal Pharmaceuticals.

Information on this page was last updated on 3/5/2025.

Shannon T. Kelley Insider Trading History at Madrigal Pharmaceuticals

See Full Table

Shannon T. Kelley Buying and Selling Activity at Madrigal Pharmaceuticals

This chart shows Shannon T Kelley's buying and selling at Madrigal Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$76ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$50k$0$50kTotal Insider BuyingTotal Insider Selling

Madrigal Pharmaceuticals Company Overview

Madrigal Pharmaceuticals logo
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Read More

Today's Range

Now: $327.87
Low: $324.02
High: $336.79

50 Day Range

MA: $332.93
Low: $293.64
High: $355.88

2 Week Range

Now: $327.87
Low: $189.00
High: $377.46

Volume

195,806 shs

Average Volume

391,905 shs

Market Capitalization

$7.24 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A